Chronic Kidney Disease in Children Aged 6-15 Years and Associated Risk Factors in Apizaco, Tlaxcala, Mexico, a Pilot Study.


Journal

Nephron
ISSN: 2235-3186
Titre abrégé: Nephron
Pays: Switzerland
ID NLM: 0331777

Informations de publication

Date de publication:
2019
Historique:
received: 06 06 2019
accepted: 05 08 2019
pubmed: 6 9 2019
medline: 11 7 2020
entrez: 6 9 2019
Statut: ppublish

Résumé

Tlaxcala, a small state in central Mexico, has the highest prevalence of chronic kidney disease (CKD) deaths in population aged 5-14 in Mexico, most of them with unknown etiology. To determine the prevalence of CKD in apparently healthy pediatric population in Apizaco, Tlaxcala. A cross-sectional pilot study was carried out in children deemed as healthy; subjects with previous diagnosis of CKD were excluded. Informed consent was obtained in all cases. A physical examination was performed, a questionnaire was applied. Blood and urine samples were obtained for serum creatinine, urinalysis, and microalbumin/creatinine ratio. A second and third evaluation was performed after 6 and 18 months in those found with urinary anomalies/CKD to confirm the diagnosis. One hundred and nine subjects completed physical examination, which are the biological samples. Median age was 12 years. CKD stage 2 was confirmed in 5 subjects in the sixth month confirmation visit (4.6%). One patient accepted renal biopsy and Alport Syndrome was found. In a robust multivariate analysis, the risk factors related to reduction in the glomerular filtration rate were males -5.15 mL/min/1.73 m2 (p = 0.002), older participants as by -1.58 mL/min/1.73 m2 per year (p < 0.0001), and among participants living close to a river -3.76 mL/min/1.73 m2 (p = 0.033). The prevalence of CKD in the population studied in Apizaco Tlaxcala was confirmed in 4.6 cases per 100 inhabitants between 6 and 15 years. Males, older age, and living close to a river were the risk predictive factors. More studies are needed to determine the causes of the high CKD prevalence in this population.

Identifiants

pubmed: 31487709
pii: 000502481
doi: 10.1159/000502481
doi:

Substances chimiques

Environmental Pollutants 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

264-273

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Manolo Ortega-Romero (M)

Departamento de Toxicología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico, Mexico.

Pablo Méndez-Hernández (P)

Departamento de Calidad y Educación en Salud, Secretaría de Salud de Tlaxcala, Tlaxcala, Mexico.
Facultad de Ciencias de la Salud, Universidad Autónoma de Tlaxcala, Tlaxcala, Mexico.

María Del Carmen Cruz-Angulo (MDC)

Hospital Infantil de Tlaxcala, Secretaría de Salud de Tlaxcala, Tlaxcala, Mexico.

Ana María Hernández-Sánchez (AM)

Unidad de Investigación en Nefrología y Metabolismo Mineral Óseo, Hospital Infantil de México Federico Gómez, Mexico, Mexico.

Ana Catalina Álvarez-Elías (AC)

Unidad de Investigación en Nefrología y Metabolismo Mineral Óseo, Hospital Infantil de México Federico Gómez, Mexico, Mexico.

Ricardo Muñoz-Arizpe (R)

Unidad de Investigación en Nefrología y Metabolismo Mineral Óseo, Hospital Infantil de México Federico Gómez, Mexico, Mexico.

Francisco Sales-Heredia (F)

Centro de Estudios sobre Derechos humanos de la Cámara de Diputados, Mexico, Mexico.

Guadalupe Aguilar-Madrid (G)

Claustro Universitario de Chihuahua, Dirección de Investigación y de Posgrado, Chihuahua, Mexico.
Departamento de Salud Pública, Facultad de Medicina, Universidad Nacional Autonoma de México, Mexico, Mexico.

Cuauhtémoc Arturo Juárez-Perez (CA)

Unidad de Investigación de Salud en el Trabajo, Centro Médico Nacional SXXI Instituto Mexicano del Seguro Social, Mexico, Mexico.

Virgilia Soto (V)

Departamento de Patología, Instituto Nacional de Cardiología, Mexico, Mexico.

Teresa Valadés (T)

Departamento de Radiología, Hospital Infantil de México Federico Gómez, Mexico, Mexico.

Nadia Olvera-Rivas (N)

Universidad Panamericana, School of Medicine, Mexico, Mexico.

Gregorio T Obrador-Vera (GT)

Universidad Panamericana, School of Medicine, Mexico, Mexico.

Olivier C Barbier (OC)

Departamento de Toxicología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico, Mexico.

Mara Medeiros (M)

Unidad de Investigación en Nefrología y Metabolismo Mineral Óseo, Hospital Infantil de México Federico Gómez, Mexico, Mexico, medeiro.mara@gmail.com.
Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autonoma de México, Mexico, Mexico, medeiro.mara@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH